Elidel, Protopic Postmarketing AEs Need Further Monitoring, FDA Says

Serious adverse events and malignancies with the topical immunosuppressants continue to concern FDA, which will take the issue, for a second time, to an advisory committee on Feb. 15. Prescriptions for the under two-year-old age group continue despite lack of approval for Elidel and Protopic in the infant population.